News

OBI Pharma announced an agreement with Threshold Pharmaceuticals, Inc. to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing…
Read More...

BioCryst Pharmaceuticals announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 is a 3-part dose ranging trial…
Read More...

Mylan announced the U.S. launch of Rasagiline Tablets, 0.5 mg and 1 mg, a generic version of the reference listed drug, Teva's Azilect Tablets. Mylan received final approval from the…
Read More...

On 3 May 2017, Lonza successfully completed the acquisition of PharmaCell B.V., one of the most-respected cell and gene contract manufacturers in Europe with employees in Maastricht and…
Read More...

Roche announced US Food and Drug Administration (FDA) approval of the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC)…
Read More...

Array BioPharma and Bristol-Myers Squibb Company announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of…
Read More...

Ligand Pharmaceuticals Incorporated announces it will receive $10 million from a contractually specified royalty rate buy-down following the sale by CorMatrix Cardiovascular, Inc. of…
Read More...

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced today that they have extended their drug discovery…
Read More...

Synthetic Genomics and Advaxis announced that they have completed development and deployment of the first current good manufacturing practice (cGMP) synthetic biology facility for the…
Read More...

Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide license agreement with Menlo Park, California-based xCella Biosciences, Inc. Under the license, xCella will…
Read More...

New research conducted by scientists at the University of Sheffield into a drug candidate which could help to delay the onset of motor neurone disease has shown encouraging early…
Read More...

AstraZeneca announced that, effective 1 June 2017, the Board has appointed Professor Nazneen Rahman as a Non-Executive Director of AstraZeneca PLC. On appointment, Professor Rahman also…
Read More...

TaiGen Biotechnology has submitted a New Drug Application (NDA) for Taigexyn (Nemonoxacin)intravenous formulation to China Food and Drug Administration (CFDA). Taigexyn is a novel…
Read More...

BioPharma Services has successfully completed 3 inspections this month by the US FDA, with concurrent audits at both research centers in Toronto, Canada, and Columbia, Missouri. Over…
Read More...

Bluebee and MediSapiens enters a partnership to provide customers with tailored end-to-end analytical solutions for Next Generation Sequencing (NGS) data. Sequencing technology is…
Read More...

Compugen Ltd board of directors has appointed Michal Preminger (PhD, MBA, Executive Director at Harvard University Office of Technology Development's Harvard Medical School site) as…
Read More...

Recipharm has appointed  Shabbir Mostafa as Director, Business Management UK & Ireland with responsibility for supporting customers in the UK & Ireland and to driving up sales.…
Read More...

Avista Pharma Solutions announced that Minneapolis Medical Research Foundation (MMRF) has selected Avista Pharma to manufacture an opioid-derived small molecule. The research is funded…
Read More...

Hovione announced that it will soon initiate recruitment for its Phase 1 clinical trial of HY02. This first in human study is a double-blinded, randomized trial, which will include…
Read More...

Lysogene has completed the enrollment in its “Sanfilippo A Multi-national Observational Study” (SAMOS). Sanfilippo A is also known as Mucopolysaccharidosis Type IIIA (MPS IIIA).…
Read More...